Premium
Peritoneal carcinomatosis from non‐gynecologic malignancies
Author(s) -
Sadeghi Babak,
Arvieux Catherine,
Glehen Olivier,
Beaujard Annie C.,
Rivoire Michel,
Baulieux Jacques,
Fontaumard Eric,
Brachet Alain,
Caillot Jean L.,
Faure Jean L.,
Porcheron Jack,
Peix Jean L.,
François Yves,
Vignal Jacques,
Gilly François N.
Publication year - 2000
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o
Subject(s) - medicine , peritoneal carcinomatosis , ascites , stage (stratigraphy) , gastroenterology , pancreatic cancer , cancer , carcinoma , colorectal cancer , surgery , paleontology , biology
BACKGROUND Peritoneal carcinomatosis (PC) is a common evolution of digestive cancer, associated with a poor prognosis. Yet it is poorly documented in the literature. METHODS Three hundred seventy patients with PC from non‐gynecologic malignancies were followed prospectively: the PC was of gastric origin in 125 cases, of colorectal origin in 118 cases, of pancreatic origin in 58 cases, of unknown origin in 43 cases, and of miscellaneous origins in 26 cases. A previously reported PC staging system was used to classify these 370 patients. RESULTS Mean and median overall survival periods were 6.0 and 3.1 months, respectively. Survival rates were mainly affected by the initial PC stage (9.8 months for Stage I with malignant peritoneal granulations less than 5 mm in greatest dimension, versus 3.7 months for Stage IV with large, malignant peritoneal masses more than 2 cm in greatest dimension). The presence of ascites was associated with poor survival of patients with gastric or pancreatic carcinoma. Differentiation of the primary tumor did not influence the prognoses of patients with PC. CONCLUSIONS A better knowledge of the natural history of PC is needed, in view of the many Phase I, II, and III trials currently being conducted to evaluate aggressive multimodal therapeutic approaches to treating patients with PC from non‐gynecologic malignancies. Cancer 2000;88:358–63. © 2000 American Cancer Society.